Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis).
作者信息
Reichle Albrecht, Heudobler Daniel, Gerner Christopher, Pantziarka Pan, Martinelli Eugenio, Holler Ernst, Corsi Francesca, Ghibelli Lina
机构信息
Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Faculty Chemistry, Institut for Analytical Chemistry, University Vienna, Vienna, Austria.
出版信息
Front Oncol. 2020 Sep 2;10:1675. doi: 10.3389/fonc.2020.01675. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis).
Front Oncol. 2020 Sep 2;10:1675. doi: 10.3389/fonc.2020.01675. eCollection 2020.
2
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.
Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018.
3
Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.
Int J Mol Sci. 2018 Nov 9;19(11):3540. doi: 10.3390/ijms19113540.
4
Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.
Front Oncol. 2019 Dec 20;9:1408. doi: 10.3389/fonc.2019.01408. eCollection 2019.
5
A Computational Model of Tumor Growth and Anakoinosis.
Front Pharmacol. 2019 Mar 26;10:287. doi: 10.3389/fphar.2019.00287. eCollection 2019.
6
Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity.
Front Oncol. 2022 Sep 13;12:1005381. doi: 10.3389/fonc.2022.1005381. eCollection 2022.
7
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.
Cancer Microenviron. 2015 Aug;8(2):75-92. doi: 10.1007/s12307-015-0170-1. Epub 2015 Aug 11.
8
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.
Front Oncol. 2024 Jan 11;13:1289222. doi: 10.3389/fonc.2023.1289222. eCollection 2023.
9
Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis.
Front Pharmacol. 2021 Oct 7;12:779021. doi: 10.3389/fphar.2021.779021. eCollection 2021.
10
Systems biology: a therapeutic target for tumor therapy.
Cancer Microenviron. 2008 Dec;1(1):159-70. doi: 10.1007/s12307-008-0012-5. Epub 2008 Jul 23.
本文引用的文献
1
Low-dose azacitidine, pioglitazone and all- retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase.
Haematologica. 2024 Apr 1;109(4):1274-1278. doi: 10.3324/haematol.2023.283864.
2
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.
Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018.
3
Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML.
Front Pharmacol. 2018 Nov 13;9:1279. doi: 10.3389/fphar.2018.01279. eCollection 2018.
4
Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
Leukemia. 2018 Aug;32(8):1671-1678. doi: 10.1038/s41375-018-0219-5. Epub 2018 Jul 19.
5
Biomodulatory therapy induces complete molecular remission in chemorefractory acute myeloid leukemia.
Haematologica. 2015 Jan;100(1):e4-6. doi: 10.3324/haematol.2014.115055. Epub 2014 Sep 26.
Zotero 插件